Cariprazine in the treatment of schizophrenia: a proof-of-concept trial.

There was a numerically higher response rate (≥20% improvement from baseline in PANSS total score) at Week 6 for cariprazine patients (1.5–4.5 mg/day: 43%, and 6–12 mg/day: 35%) versus placebo (31%), but the difference did not reach statistical significance in the overall or the pairwise comparisons with placebo.

also in 111,027 other papers